Semaglutide, marketed under brand names including Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management
[1] [2] Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight management as an adjunct to reduced-calorie diet and increased physical activity), tirzepatide represents the first dual incretin receptor agonist available in clinical practice
Nutritional Deficiencies: Ozempic can reduce appetite and food intake, potentially leading to insufficient intake of nutrients essential for hair health, such as protein, iron, zinc, and vitamins
Naltrexone works by blocking the effect of brain receptors and decreasing cravings and urges to use alcohol
They increase feelings of satiety, making you feel full after a smaller portion than normal
Overall, however, CSF may have the highest potential to differentiate between mutations in the primary tumor and corresponding BM